Literature DB >> 26617760

Tankyrase 1 polymorphism associated with an increased risk in developing non-small cell lung cancer in a Chinese population: a proof-of-principle study.

Ying Wang1, Weiyu Jiang2, Xiaogu Liu1, Yongjun Zhang3.   

Abstract

OBJECTIVES: Tankyrase 1 (TNKS1), a poly (ADP-ribose) polymerase, regulates telomere length and apoptosis in cells, overexpression of which occurred in non-small cell lung cancer (NSCLC). This study investigated TNKS1 single-nucleotide polymorphisms (SNPs) for association with a risk in NSCLC development in a Chinese population.
METHODS: NSCLC cases and healthy controls of 500 each were recruited for genotyping of 24 TNKS1 SNPs. The association between genotype and NSCLC risk was evaluated by computing the odds ratio (OR) and 95% confidence interval (CI) with multivariate unconditional logistic regression analyses. Haploview software was to analyze association between haplotypes and NSCLC risk.
RESULTS: TNKS1 rs6601328 A allele was associated with a lower risk in developing NSCLC and adenocarcinoma (ADC) (OR=0.71; 95% CI, 0.51-0.99 and OR=0.70; 95% CI, 0.50-0.99), whereas TNKS1 rs11991621 C allele (OR=1.44; 95% CI, 1.03-2.03), rs11991621 C/C (OR=1.44, 95% CI, 1.03-2.35; P=0.03), and rs10503380 G/G (OR= 1.56, 95% CI, 1.09-2.50, P=0.02) were associated with a higher risk in developing NSCLC or ADC in females and rs6601328 A/A major allele (OR=1.39; 95% CI, 1.00-1.92; P=0.047) and rs7015700 G/G (OR= 1.51, 95% CI, 1.04-2.21) was associated with an increased NSCLC or ADC risk in males but a reduced NSCLC risk (OR=0.63; 95% CI, 0.42-0.96) and ADC risk (OR=0.64; 95% CI, 0.42-0.97) in females. Haploview showed that there were three Haplotype Blocks associated with NSCLC risk. However, TNKS1 rs12541709 C/C was associated with protective effect against ADC (OR=0.75; 95% CI, 0.56-0.99; P=0.04) in this Chinese population.
CONCLUSION: TNKS1 SNPs (rs11991621 rs10503380, and rs7015700) were associated with NSCLC risk, whereas rs6601328 and rs12541709 inversely associated with NSCLC or ADC risk in this Chinese population.

Entities:  

Keywords:  Non-small cell lung cancer; TNKS1; genetic susceptibility; single nucleotide polymorphisms

Mesh:

Substances:

Year:  2015        PMID: 26617760      PMCID: PMC4637575     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  33 in total

1.  Tankyrase 1 interacts with Mcl-1 proteins and inhibits their regulation of apoptosis.

Authors:  Jeehyeon Bae; Jill R Donigian; Aaron J W Hsueh
Journal:  J Biol Chem       Date:  2002-12-09       Impact factor: 5.157

2.  Neuronal acetylcholine receptor subunit alpha-9 (CHRNA9) polymorphisms are associated with NSCLC risk in a Chinese population.

Authors:  Ying Wang; Yongjun Zhang; Cuiping Gu; Wenlong Bao; Yejiang Bao
Journal:  Med Oncol       Date:  2014-03-28       Impact factor: 3.064

Review 3.  TERT genetic polymorphism rs2736100 was associated with lung cancer: a meta-analysis based on 14,492 subjects.

Authors:  Hui-Min Wang; Xue-Yan Zhang; Bo Jin
Journal:  Genet Test Mol Biomarkers       Date:  2013-12

4.  Tankyrase, a poly(ADP-ribose) polymerase at human telomeres.

Authors:  S Smith; I Giriat; A Schmitt; T de Lange
Journal:  Science       Date:  1998-11-20       Impact factor: 47.728

5.  WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.

Authors:  Don X Nguyen; Anne C Chiang; Xiang H-F Zhang; Juliet Y Kim; Mark G Kris; Marc Ladanyi; William L Gerald; Joan Massagué
Journal:  Cell       Date:  2009-07-02       Impact factor: 41.582

6.  Gender effects of the COMT Val 158 Met genotype on verbal fluency in healthy adults.

Authors:  Marcio Gerhardt Soeiro-De-Souza; Danielle Soares Bio; Denise Petresco David; Giovani Missio; Bruno Lima; Fernando Fernandes; Rodrigo Machado-Vieira; Ricardo Alberto Moreno
Journal:  Mol Med Rep       Date:  2013-07-01       Impact factor: 2.952

7.  Silencing tankyrase and telomerase promotes A549 human lung adenocarcinoma cell apoptosis and inhibits proliferation.

Authors:  Hongda Lu; Zhang Lei; Zhongxin Lu; Qianming Lu; Chi Lu; Weiqun Chen; Chun Wang; Qiu Tang; Qingzhi Kong
Journal:  Oncol Rep       Date:  2013-08-08       Impact factor: 3.906

8.  Evidence for tankyrases as antineoplastic targets in lung cancer.

Authors:  Alexander M Busch; Kevin C Johnson; Radu V Stan; Aarti Sanglikar; Yashi Ahmed; Ethan Dmitrovsky; Sarah J Freemantle
Journal:  BMC Cancer       Date:  2013-04-28       Impact factor: 4.430

9.  Pleiotropic associations of risk variants identified for other cancers with lung cancer risk: the PAGE and TRICL consortia.

Authors:  S Lani Park; Megan D Fesinmeyer; Maria Timofeeva; Christian P Caberto; Jonathan M Kocarnik; Younghun Han; Shelly-Ann Love; Alicia Young; Logan Dumitrescu; Yi Lin; Robert Goodloe; Lynne R Wilkens; Lucia Hindorff; Jay H Fowke; Cara Carty; Steven Buyske; Frederick R Schumacher; Anne Butler; Holli Dilks; Ewa Deelman; Michele L Cote; Wei Chen; Mala Pande; David C Christiani; John K Field; Heike Bickebller; Angela Risch; Joachim Heinrich; Paul Brennan; Yufei Wang; Timothy Eisen; Richard S Houlston; Michael Thun; Demetrius Albanes; Neil Caporaso; Ulrike Peters; Kari E North; Gerardo Heiss; Dana C Crawford; William S Bush; Christopher A Haiman; Maria Teresa Landi; Rayjean J Hung; Charles Kooperberg; Christopher I Amos; Loïc Le Marchand; Iona Cheng
Journal:  J Natl Cancer Inst       Date:  2014-03-28       Impact factor: 13.506

10.  Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer.

Authors:  Baozhi Chen; Michael E Dodge; Wei Tang; Jianming Lu; Zhiqiang Ma; Chih-Wei Fan; Shuguang Wei; Wayne Hao; Jessica Kilgore; Noelle S Williams; Michael G Roth; James F Amatruda; Chuo Chen; Lawrence Lum
Journal:  Nat Chem Biol       Date:  2009-01-04       Impact factor: 15.040

View more
  1 in total

Review 1.  Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.

Authors:  Joshua M Kaplan; Neeraj Sharma; Sean Dikdan
Journal:  Int J Mol Sci       Date:  2018-01-29       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.